Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | QPCT | Q16769 | 3/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | C5 | P01031 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19445850 | 0.92 | NPC1 (0.42) | LMNAMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL12515235 | 0.90 | LMNA (0.41) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL13973703 | 0.90 | HSD17B10 (0.40) | LMNAMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL13815082 | 0.89 | AAK1 (0.44) | LMNAMEN1KMT2APOLB | |
| SCHEMBL15317942 | 0.84 | LMNA (0.46) | LMNAMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL19445763 | 0.84 | LMNA (0.40) | LMNAMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL10260923 | 0.84 | NPY4R (0.39) | LMNAMEN1KMT2A | |
| SCHEMBL12515508 | 0.83 | ALDH1A1 (0.41) | LMNAMEN1KMT2APOLB | |
| SCHEMBL10262220 | 0.83 | ALDH1A1 (0.41) | LMNAMEN1KMT2APOLB | |
| SCHEMBL13973757 | 0.83 | MMP2 (0.41) | LMNAMEN1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802683-B2 | Compounds for use in treatment of mucositis | CELLCEUTIX CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | LMNA 3004/4885MEN1 2352/4885KMT2A 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.